Top 20 global biopharma companies report 2.3 per cent market cap growth in Q2 2023: GlobalData
Market cap surged from $3.49 trillion during the first quarter (Q1) of 2023 to $3.56 trillion in Q2 2023
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
AbbVie
Lupin receives USD 25 million from AbbVie for successful initiation of Phase 1 clinical studies
Lupin and AbbVie inked the licensing, development, and commercialisation agreement in 2018 for this novel oncology drug to treat…
AbbVie’s Rinvoq for Crohn’s Disease to see rapid uptake by healthcare providers: GlobalData
It is expected that the prescribing patterns of Rinvoq by HCPs will follow an ongoing trend by gastroenterologists to be more…
AbbVie and Eli Lilly exit UK drug pricing agreement
The Association of British Pharma Industry (ABPI) said it was seeking early talks with the government to set out a new future…
Abbvie raises sales outlook of two new drugs to more than $17.5 billion in 2025
The company's previous sales outlook for Skyrizi and Rinvoq in 2025 was more than $15 billion
AbbVie and Cugene announce collaboration in autoimmune diseases
Under the terms of the agreement, Cugene will receive an upfront payment of $48.5 million, and will also be eligible to receive…
Dragonfly and AbbVie expand collaboration in oncology and autoimmune disease
Companies to develop additional drug candidates in immune-mediated diseases using Dragonfly's proprietary Tri-specific NK cell…
US FDA extends review period for expanded use of Abbvie’s psoriasis drug
The US Food and Drug Administration (FDA) was reviewing the application for the use of Skyrizi in patients aged 16 years or older…
US FDA approves second indication for Skyrizi to treat adults with active psoriatic arthritis
Skyrizi maintains a dosing regimen for PsA that is consistent with the existing regimen for moderate-to-severe plaque psoriasis…
US FDA approves drugs from AbbVie and Pfizer to treat eczema
AbbVie’s Rinvoq and Pfizer’s Cibinqo have been approved to treat moderate-to-severe eczema, in patients who do not respond to…